Abstract 3951: AKT inhibitor capivasertib combines with dexamethasone and venetoclax to enhance anti-tumor responses in the preclinical models of childhood acute lymphoblastic leukemia
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Brandon Willis, Nadezda Bryan, Justine Roderick-Richardson, Alan Rosen, Lori Chan, Simon T. Barry
Institution: AstraZeneca (United States)
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409630195